Describe the application status of different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), observe the therapeutic efficacy and safety of the treatment modalities.

Evaluated the efficacy and safety of different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL)

Inclusion Criteria:

• Age ≥ 18 years old
• Initial or first recurrent iNHL confirmed by histopathology, including FL (1-3a), MZL, MCL;
• Sign an informed consent form;
• Researchers evaluate patients who can benefit from receiving immunochemotherapy.

Exclusion Criteria:

• There are contraindications to any medication in the treatment plan;
• Pregnant or lactating women or male and female participants of childbearing age did not take contraceptive measures during the trial period and within 30 days after the last medication;
• Researchers believe that patients who are not suitable for enrollment.

Eligibale patients who ≥ 18 years old, Initial or first recurrent iNHL, with no contraindications to any medication in the treatment plan are enrolled. They will sign an informed consent form. Pregnant or lactating women were excluded. And patients who may not benefit from receiving immunochemotherapy evaluated by researchers are also excluded.